

ISSN 1365-3113
www.systrevpharm.org

Volume 17(1)
No. 1 February 1, 2010

Systematic Reviews in Pharmacy

An Official Publication of the Royal Pharmaceutical Society

www.systrevpharm.org



Systematic Reviews in Pharmacy is a peer-reviewed journal, published quarterly, covering all aspects of pharmacy practice, including clinical, community, and pharmaceutical care. The journal is published by the Royal Pharmaceutical Society, London, UK. For more information, please contact the editorial office at systrevpharm@rps.ac.uk.

Wiley-Blackwell | Health



Systematic Reviews in Pharmacy



25+ Million Readerbase

[Online First](#)

[Archive](#)

[Aims and Scope](#)

[Abstracting & Indexing](#)

[Most Accessed Articles](#)

[Most Downloaded Articles](#)



Recommended Conferences

July 10-11, 2023

[6th International Pharmacy and Pharmaceutical Conference](#)

Dubai, UAE

July 13-14, 2023

[8th International Conference on Molecular Medicine and Diagnostics](#)

Dubai, UAE

July 13-14, 2023

[4th International Conference on Pharmaceutical Chemistry](#)

Dubai, UAE

[Google Scholar citation report](#)

Citations : 9175

[Systematic Reviews in Pharmacy received 9175 citations as per google scholar report](#)



Systematic Reviews Pharmacy

FOLLOW

GET MY OWN PROFILE

Editor


Verified email at sysrevpharma.org - [Homepage](#)

Pharmacy Pharmaceutical sciences pharmacology Biochemistry Biomedicine

TITLE	CITED BY	YEAR
Nanoemulsion: A pharmaceutical review. P Shah, D Bhalodia, P Shelat Systematic reviews in pharmacy 1 (1)	399	2010
Emulsion micro emulsion and nano emulsion: a review SN Kale, SL Deore Systematic Reviews in Pharmacy 8 (1), 39	279	2017
COVID-19 pandemic and home online learning system: Does it affect the quality of pharmacy school learning M Suryaman, Y Cahyono, D Muliansyah, O Bustani, P Suryani, M Fahlevi, ... Systematic Reviews in Pharmacy 11 (8), 524-530	158	2020
Optimization of MSMEs empowerment in facing competition in the global market during the COVID-19 pandemic time A Affandi, AS Sarwani, H Erlangga, AO Siagian, A Purwanto, AA Effendy, ... Systematic Reviews in Pharmacy 11 (11), 1506-1515	107	2020
Biopharmaceutics classification system H Chavda, C Patel, I Anand Systematic reviews in pharmacy 1 (1), 62	106	2010
University students online learning system during Covid-19 pandemic: Advantages, constraints and solutions NA Fatonia, E Nurkhayatic, E Nurdiauwatid, GP Fidziahe, S Adhag, ... Systematic Reviews in Pharmacy 11 (7), 570-576	93	2020
Coumarins: the antimicrobial agents YK Al-Majedy, AAH Kadhum, AA Al-Amiery, AB Mohamad Systematic Reviews in Pharmacy 8 (1), 62	91	2017
Ophthalmic drug delivery system: challenges and approaches P Patel, D Shastri, P Shelat, A Shukla Systematic Reviews in Pharmacy 1 (2), 113	85	2010

Cited by [VIEW ALL](#)

	All	Since 2017
Citations	9175	8587
h-index	36	35
i10-index	225	219



[Systematic Reviews in Pharmacy peer review process verified at publons](#)

publons BROWSE COMMUNITY FAQ

Home > Journals/Conferences > Journal/Conference Details

Systematic Reviews in Pharmacy

REVIEW POLICY ON PUBLONS

- Does not allow reviews to be publicly displayed
- Only allows reviewers to display the journal they reviewed for

REVIEWS
Total: 30

In accordance with Systematic Reviews in Pharmacy's editorial policy, review content is not publicly displayed on Publons.

INTERESTED IN REVIEWING FOR THIS JOURNAL?
We can put registered members of Publons' reviewer community in touch with partnered journals they would like to review for. [Register now](#) to let Systematic Reviews in Pharmacy know you want to review for them.

TOP HANDLING EDITORS ON PUBLONS (MANUSCRIPTS HANDLED)
AP (1) Arvind Pandey

EDITORIAL BOARD MEMBERS ON PUBLONS
Publons users have indicated that they sit on Systematic Reviews in Pharmacy's editorial board but we are unable to verify these claims. If you are an administrator for Systematic Reviews in Pharmacy, please get in touch to find out how you can verify the contributions of your editorial board members and more.

ENDORSED BY
RS HS MM SA

JOURNAL/CONFERENCE ENDORSEMENT
[ENDORSE THIS JOURNAL](#)

Indexed In

- > Genamics JournalSeek
- > JournalTOCs
- > China National Knowledge Infrastructure (CNKI)
- > Scimago
- > Ulrich's Periodicals Directory
- > EBSCO A-Z
- > Pollution Abstracts
- > OCLC- WorldCat
- > Proquest Summons
- > ROAD
- > CABI full text
- > SciLit - Scientific Literature
- > Publons
- > Google Scholar
- > J-Gate
- > Chemical Abstract
- > SHERPA ROMEO
- > Bielefeld Academic Search Engine (BASE)
- > SCILIT

- › Baidu Scholar
- › Dimensions
- › Index Copernicus
- › JournalGuide
- › Microsoft Academic
- › ReadCube

Tweets from @in_systematic

Follow on Twitter

Reviews in Pharmacy @in_systematic · Apr 1



An experimental device can improve blood sugar control in patients who developed [#diabetes](#) after removal of [#pancreas](#)



Reviews in Pharmacy @in_systematic · Apr 1



Share featured papers on [#biomedical](#) research for the inaugural volume [@in_systematic](#)



Reviews in Pharmacy @in_systematic · Mar 31



Editorial Board

Editorial Board

FILIPIC Bratko, PhD

Professor, Department of Experimental and Translation Oncology

Croatian Institute for experimental and translation oncology, Zagreb, Croatia, Croatia

Dr Lucius, MBBS

General Practice

Ludwig Maximilians University Munich, Germany

Dr. Aygul Z. Ibatova

Department of Natural Sciences

Tyumen Industrial University, Scopus Author ID: 57191110632 <http://orcid.org/0000-0003-0565-8533>, Russia

Dr Ahmad Faisal Ismail

Kulliyah of Dentistry

International Islamic University Malaysia, Kuantan Campus, 25200 Kuantan, Pahang, Scopus Author ID: 35388596700, Malaysia

Dr. Huiliang ZHAO, Ph.D

Guizhou Minzu University, Huaxi District, Guiyang, China

Dr. Mohd Armi Abu Samah

International Islamic University Malaysia, (IIUM) 25200 Kuantan Pahang

Dr. Baded ramji

Sri Lanka

Dr. Chris randea

South Africa

Dr. Yingwen ZHAO

Researcher of Guizhou Rural Economic and Social Development Research Institute, China

Dr. Li Zihan, Ph.D

University of Glasgow, UK

Gabriela Cioca

Faculty of Medicine, Pharmacology Department

Lucian Blaga University of Sibiu, Romania, Lucian Blaga street, no 2A, Sibiu, Romania

Dariusz Nowak

Municipal Hospital, Mickiewicza street no 12, 42-200 Czestochowa, Poland

Aleksandra Zyska
Faculty of Medicine, Department of Physiology
Opole University, Oleska street no 48, 45-052 Opole, Poland

Katarzyna Sznajder
Faculty of Medicine, Clinical Department of Diagnostic Imaging
Opole University, Oleska street no 48, 45-052 Opole, Poland

Jacek Jędrzak
Faculty of Medicine, Department of Family Medicine and Public Health
Opole University, Oleska street no 48, 45-052 Opole, Poland

Luciano Benedini
Universidad Nacional del Sur (National University of South-UNS), Bahía Blanca 8000, Argentina

Paula Messina
Departamento de Biología
Universidad Nacional del Sur (National University of South-UNS), Bioquímica y Farmacia, Bahía Blanca 8000, Argentina

Michael Walsh
Washington State University, College of Pharmacy and Pharmaceutical Sciences (CPPS), USA

Prof. Dr. Kittisak Jermsittiparsert
Henan University, China

Amel Dawod Kamel Gudia, PhD
Faculty of nursing
Cairo University, Egypt

Arif Nur Muhammad Ansori
Airlangga University, Scopus Author ID: 57195995342, <https://orcid.org/0000-0002-1279-3904>, Indonesia

Mohammed Nader Shalaby
Suez Canal University, Associate Professor of Biological Sciences and Sports Health, Egypt

Dr. Faten Abo-Aziza Mohamed, PhD
Associate Professor, Clinical Pathology and Stem Cell Research
National Research Centre, Manager of Veterinary Division Central Lab (605), 33 El-Behoos St, Dokki, Cairo, Egypt

Professor Asim Ahmed Elnour Ahmed
College of Pharmacy
Al-Ain University of Science and Technology, UAE

S. Parasuraman, M.Pharm., Ph.D
AIMST University, Malaysia

Ebenezer Wiafe, PhD
Pharmacy
University of Kwazulu-Natal, South Africa

Editor-in-Chief

Dr. Ayad F. Alkaim
University of Babylon, College of Science for Women, Babylon, Scopus Author ID: 55255310600, Iraq

[Submit Article](#)

[Login](#)

[Register](#)

Most Viewed Articles

Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01

Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3

A Review of Pharmacoeconomics: the key to "Healthcare for All" Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21

Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19

Most Downloaded

Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01

Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 10.5530/srp.2019.1.2

Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4

A Review of Pharmacoeconomics: the key to "Healthcare for All" Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21

A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3

Copyright © 2023 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from or liability to Systematic Reviews in Pharmacy



Copyright © 2023 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from or liability to Systematic Reviews in Pharmacy. For best results, please use Internet Explorer or Google Chrome

POLICIES & JOURNAL LINKS

- [Advertising Policy](#)
- [Author's Rights and Obligations](#)
- [Conflict of Interest Policy](#)
- [Digital Archiving & Preservation Policies](#)
- [Editorial Policies](#)
- [Peer Review Policy](#)
- [Editorial & Peer Review Process](#)
- [License Information](#)
- [Plagiarism Policy](#)
- [Privacy Policy](#)
- [Protection of Research Participants \(Statement On Human And Animal Rights\)](#)
- [Publishing Ethics](#)
- [Corrections, Retractions & Expressions of Concern](#)
- [Self-Archiving Policies](#)
- [Statement of Informed Consent](#)
- [Terms of Use](#)



25+ Million Readerbase

[Online First](#)

[Archive](#)

[Aims and Scope](#)

[Abstracting & Indexing](#)

[Most Accessed Articles](#)

[Most Downloaded Articles](#)



Recommended Conferences

July 10-11, 2023

[6th International Pharmacy and Pharmaceutical Conference](#)

Dubai, UAE

July 13-14, 2023

[8th International Conference on Molecular Medicine and Diagnostics](#)

Dubai, UAE

July 13-14, 2023

[4th International Conference on Pharmaceutical Chemistry](#)

Dubai, UAE

[Google Scholar citation report](#)


Citations : 9175

[Systematic Reviews in Pharmacy received 9175 citations as per google scholar report](#)

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.23

Review Article

[Duck Meat, Delicious yet low in Unsaturated Fat; Comparative Study between Duck Meat Consumption in ASEAN toward the Number of COVID Cases](#)


 Maslichah Mafruchati

SRP. 2020; 11(10): 519 - 523

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.78

Research Article

[Non-Toxic Fractions of Streptomyces hygroscopicus Subsp. Hygroscopicus Metabolite Suppressed the Growth of Plasmodium Falciparum in Vitro Possibly through L-malate: Quinone Oxidoreductase \(PfMQO\) Mitochondrial Enzyme Inhibition](#)

 Alfian Wika Cahyono, Loeki Enggar Fitri, Nafisatuzzamrudah, Rivo Yudhinata Brian Nugraha, Rara Aulia, Fitria Febriliani, Dio Giovanni Ariel, Kana Mardhiyyah, Sri Winarsih, [Suciati](#), Dian Japany, Erwahyuni Endang, Danang Waluyo

SRP. 2020; 11(10): 524 - 531

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.79

Review Article

[Activization of Cognitive Activity of Students in Higher Education Institutions](#)

 Alona Prokopenko, Alla Vozniuk, Hennadii Leshchenko, Liliya Manchulenko, Alla Kramarenko, Oksana Mondich

SRP. 2020; 11(10): 144 - 146

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.24

Review Article

[Factors Affecting Entrepreneurial Student Intention in Learning Technology](#)

 Bambang Leo Handoko, Septi Wifasari, Fahry Priandhana

SRP. 2020; 11(10): 532 - 536

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.80

Research Article

[Mechanism of Bone Metabolism Interruption Due to High Intensity Physical Exercise](#)


 Gadis Meinar Sari, Soetjipto, Lilik Herawati.

SRP. 2020; 11(10): 836 - 843

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.125

Review Article

[The Impact of European Educational Integration on the Process Study of Foreign Languages in Institutions of Higher Education of Ukraine](#)

 Vasyl Zheliaskov, Volodymyr Krasnopolskyi, Tetiana Sharhun, Victoriia Ihnatenko, Iryna Hinsirovska, Oksana Tymofyeyeva

SRP. 2020; 11(10): 147 - 155

[» Abstract](#) [» PDF](#) DOI: 10.31838/srp.2020.10.25

Research Article

Non-Toxic Fractions of *Streptomyces hygroscopicus* Subsp. *Hygroscopicus* Metabolite Suppressed the Growth of *Plasmodium Falciparum* in Vitro Possibly through L-malate: Quinone Oxidoreductase (PfMQO) Mitochondrial Enzyme Inhibition

Alfian Wika Cahyono¹, Loeki Enggar Fitri^{2*}, Nafisatuzzamrudah³, Rivo Yudhinata Brian Nugraha², Rara Aulia³, Fitria Febriliani⁴, Dio Giovanni Ariel⁴, Kana Mardhiyyah⁵, Sri Winarsih⁶, Suciati⁷, Dian Japany⁸, Erwahyuni Endang⁸, Danang Waluyo⁸

¹ Doctoral Programs in Medical Science, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

² Department of Parasitology - Malaria Research Group, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

³ Master Program in Biomedical Science, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

⁴ Study Programs of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

⁵ Department of Biochemistry and Biomolecular, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

⁶ Department of Microbiology - Department of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

⁷ Department of Pharmacognosy & Phytochemistry, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia

⁸ Laboratory for Biotechnology, Agency for the Assessment and Application of Technology, Building 630, Puspiptek Area, Banten, Indonesia

Corresponding author: Loeki Enggar Fitri

Department of Parasitology - Malaria Research Group, Faculty of Medicine, Universitas Brawijaya Malang, Indonesia

Email: lukief@ub.ac.id

ABSTRACT

Introduction: Previous research has proven that ethyl acetate extract of *Streptomyces hygroscopicus* can inhibit *Plasmodium* growth *in vivo* and *in vitro* through inhibition of the Proteasome ubiquitin system. In this study, we analyzed the activity of several fractions of *S. hygroscopicus* toward the growth of *P. falciparum* culture with specific targets on the mitochondrial enzyme of *P. falciparum*; L-malate: quinone oxidoreductase (PfMQO) and dihydroorotate dehydrogenase (PfDHODH). **Methodology:** the fractionation process uses the *Flash Column Chromatography* (FCC) BUCHI Reveleris® PREP, analyzed using thin layer chromatography (TLC). The antimalarial activity of the fractions was tested on the culture of *P. falciparum* 3D7 using enzyme lactate dehydrogenase (PfLDH) assay and their activity toward PfMQO and PfDHODH target enzymes. The fractions analyzed using HPLC and compared to the standard *dihydroeponemycin*. The toxicity of the fractions, the WST-8 assay was conducted. **Results:** of the 30 fractions produced, 6 fractions were able to suppress the *P. falciparum* and two of them were able to inhibit more than 50% of *P. falciparum* growth. Both of these fractions were proven to inhibit the activity of the PfMQO enzyme but had no inhibition of the PfDHODH enzyme. Both fractions reduced human cell viability by less than 50% in toxicity test. HPLC analysis indicated that besides *dihydroeponemycin*, there were other compounds presences in the extract. **Conclusions:** fractions of *S. hygroscopicus* metabolite contains non-toxic compounds in addition to *dihydroeponemycin* that could suppress the growth of *P. falciparum* *in vitro*. This potential effect might be related to the inhibition of PfMQO enzyme.

Keywords: Fractions, *Streptomyces hygroscopicus*, *P. falciparum*, PfDHODH, PfMQO, LDH

Correspondence:

Loeki Enggar Fitri

Department of Parasitology - Malaria Research Group, Faculty of Medicine, Universitas Brawijaya Malang, Indonesia

Email: lukief@ub.ac.id

INTRODUCTION

Plasmodium falciparum is one of the types of malaria-causing parasites that can provide severe clinical manifestations of malaria. The mechanism of action of the drug toward *Plasmodium* determines the therapeutic success of malaria. Mitochondria are organelles that have an important role in several metabolic pathways for parasite survival. In the parasite metabolic system, glycolysis, the tri carboxyl acid (TCA) and mitochondrial electron transport chain (ETC) cycles are a potential target in the development of anti-parasitic drugs [1,2]. *Plasmodium falciparum* dihydroorotate dehydrogenase (PfDHODH) and *Plasmodium falciparum* L-malate: quinone oxidoreductase (PfMQO) have proven to act as a very important enzymes in the life of asexual parasites [3, 4]. PfDHODH which is needed by the *Plasmodium* in pyrimidine biosynthesis has become a potential target of malaria treatment [3], while PfMQO is the one of dehydrogenase enzyme that has important role in ETC and

TCA cycle only found in *Plasmodium* and lacked in humans thus PfMQO could also be served as potential drug target for antimalaria [4].

Streptomyces hygroscopicus is a gram-positive bacterium found in soil. As part of the Actinomycetes family, *S. hygroscopicus* is known contains many secondary metabolites, one of them is *dihydroeponemycin* that can inhibit the *Plasmodium* Ubiquitin-Proteasome System (UPS). Our previous study using Balb-c mice shown that crude extract from *S. hygroscopicus* could inhibit *Plasmodium* growth *in vivo* [5]. Our recent study showed that crude extracts of *S. hygroscopicus* also had an effect of inhibition in *Plasmodium* growth *in vitro*. In fact, the ethyl acetate extract of *S. hygroscopicus* still have many kinds of compound, thus fractionation process is needed to reduce the variation of compounds contained in each fractionation result, we assume each fraction result will contain different compounds.

Although it is well-known that *S. hygroscopicus* extract has the potential as a new candidate for malaria treatment, no toxicity test has been conducted to determine whether the drug candidate is toxic or not to human cells. Besides, a toxicity test needs to be carried out because the isolation of *S. hygroscopicus* from the soil may carry contaminants such as, heavy metals (e.g. cadmium) [6], aflatoxin which is a toxic substance [7] and potentially pathogenic microbes during the extraction process [8]. This study aims to explore the effectiveness of the *S. hygroscopicus* fractions as antimalarial and determine their cytotoxic activity *in vitro*.

MATERIAL AND METHODS

Research Design

This study uses explorative designs and true experimental laboratory *in vitro* method with posttest only controlled group design. The study compared the results obtained from the experimental group after being treated with the control group *in vitro*. In antimalarial activity test the *Plasmodium falciparum* 3D7 culture was divided into 5 groups, there were negative control group (group exposed with medium contains 2 µl DMSO 1% similar to the solvent of the fractions), positive control group (group treated with 2 µl atovaquone each well) and groups that treated with fractions of *S. hygroscopicus* dosage 50ppm, 5ppm, and 0.05ppm, respectively. For enzymes assay, we used 5 experiment groups, there were negative control group (2 µl DMSO 1% similar to the solvent of the fractions), positive control group (without reaction substrate) and fraction doses of 200ppm, 20ppm, and 2 ppm groups. In the cytotoxic activity test the fraction dose divided into ten different concentrations of 0.15625ppm, 0.3125ppm, 0.625ppm, 1.25ppm, 2.5ppm, 5 ppm, 10ppm, 20ppm, and 40 ppm. In an explorative study, we performed a High-performance liquid chromatography (HPLC) fraction compare with standard compound *dihydroeponemycin*.

The characterization of *S. hygroscopicus* subsp. *Hygroscopicus*

Streptomyces hygroscopicus subsp. *Hygroscopicus* isolate obtained from the Microbiology LIPI (LIPI-MC) Cibinong, which was subcultured in the microbiology laboratory of the Faculty of Medicine, Universitas Brawijaya. *Streptomyces* colonies were then characterized based on macroscopic colony morphology and microscopic bacterial morphology based on Gram staining.

Fermentation and extraction of the secondary metabolite of *S. hygroscopicus* subsp. *Hygroscopicus*

Fermentation was done using International *Streptomyces* Project 4 (ISP4) liquid media in aseptic conditions on erlenmeyer. Liquid media ISP4 was prepared in an erlenmeyer glass in aseptic (autoclaved) conditions of 1000 ml with medium conditions pH 5-7. Bacterial colonies were scraped from ISP4 culture medium and homogenized in ISP4 media. The ISP4 media was mixed with 100 ml of inoculum (comparison between media and inoculum 10: 1). The media then tightly closed with cotton and aluminum foil, to ensure that there is no air inside an erlenmeyer and then incubated for 5 days in a shaking incubator at 28°C at 150 rpm. After 5 days, fermented bacteria centrifuged at 3000 rpm for 10 minutes and the supernatant was taken for the extraction process [9]. The fermented product is then mixed with 1:1 ethyl acetate

(v/v) and shaken for 1 hour, then left for 1-2 hours in a separating funnel to form two layers. The bacterial metabolite will be carried to the solvent in the ethyl acetate phase. The water phase was removed and the solvent phase (ethyl acetate) was collected and evaporated in the rotary evaporator until it becomes a paste, then continued evaporated on a water bath at 40-50° C until it turns into powder and weighed before keeping in refrigerator.

Fractionation of the secondary metabolite of *S. hygroscopicus* subsp. *Hygroscopicus*

Fractionation was conducted using flash column chromatography (FCC) BUCHI Reveleris® PREP Purification System with a gradient elution system using a UV detector of 254nm, 365nm, and 366nm as well as an evaporative light scattering detector (ELSD) to obtain all compounds detected at that wavelength. Total extract sample injection to the column with a total amount of 62 mg, using 33 grams of silica gel 60. The extract used was dissolved with methanol and then injected as much as 1 mL into the injector with a syringe without a needle that had been given filter paper on the inside of the syringe and the following steps were carried out as prepared previously as the gradient eluent system. There were two solvents used, according to the results of the previous TLC, namely solvent A (n-hexane pa) and solvent B (ethyl acetate pa) with a gradient mode from 100% n-hexane to 100% ethyl acetate for 120 minutes with a flow rate of 5 ml /minute. After that, the isocratic mode was changed to 100% ethyl acetate for 10 minutes to give time to replace n-hexane with methanol pa. Flushing with methanol was carried out with gradient 100% - 0% methanol pa (to water) for 30 minutes with a flow rate of 5 ml /min so that the compounds left /stuck in the tool could be accommodated. After finishing running, the collected samples were concentrated by evaporating them in a fume hood. The purity of the fraction was then validated using the normal phase Thin Layer Chromatography (TLC).

Plasmodium falciparum 3D7 culture

The parasitic culture in the TC flask which has a parasitic degree of 10% was taken using a 5 mL disposable pipette and put in a 15 ml centrifuge tube. The culture was centrifuged at a speed of 2000 rpm for 5 minutes and the supernatant was removed. The formed packets were ready to be used for an *in vitro* assay. An *in vitro* anti-malarial activity of *S. hygroscopicus* was carried out to determine the development of parasites using LDH Assay. A new Tissue Culture (TC) 96-well plate was prepared and laid out for the anti-malarial *in vitro* test mapping was arranged including controls that contain complete mediums and all group replication.

Plasmodium falciparum lactate dehydrogenase (P/LDH) enzyme assay

The fraction which has been given 10 ul 100% DMSO with the concentration 50ppm, 5ppm, and 0.05ppm put in the well of the 96-well plate for the replication assay. Then the plate which had a fraction was put into the concentrator for 1 hour at 900g. At the same time, *Plasmodium falciparum* culture which was prepared to achieve 0.3% parasitemia put into each well of 96- plates assay as much as 190µl, then store it in the incubator for 3 days. After that PBS was added as much as 200ul to all wells then

centrifuged at 1300g for 5 minutes, the supernatant was discarded, and the plate was put in the freezer -30°C for 3 hours. LDH buffer which will be used for 30 minutes was made by mixing buffer reaction, nitro blue tetrazolium (NBT), and 3- acetyl pyridine NAD (APAD) to make Mix Assay and added to each well as much as 90µl, then placed on 650rpm shaker plate for 30 minutes and finally analyze using 650nm spectrophotometry the method has been optimized [10].

***Plasmodium falciparum* L-malate: quinone oxidoreductase (PfMQO) enzyme inhibitory assay**

Fraction of *S. hygroscopicus* metabolite was mixed with 40 µl DMSO, then put 2µl into each well with concentrations of 200ppm, 20ppm and 2ppm, then added 193µl PfMQO buffer assay (consisting of 50mM HEPES, 1mM KCN, 60 µM decylubiquinone, 120 µM, 120 µM DCIP, 2.5 µl / ml PfMQO membrane respectively). Then 5 µl of 400 mM sodium malate was added to each well in a dark room, so the final volume per well was 200 µl per well. Measurement was made using a spectrophotometer every 1 minute for 8 minutes, all procedures were carried out at 37°C.

***Plasmodium falciparum* dihydroorotate dehydrogenase (PfDHODH) enzyme inhibitory assay**

Fraction of *S. hygroscopicus* metabolite were given in each well with volume 2µl with concentrations of 200ppm, 20ppm, and 2ppm, then added 190µl PfDHODH buffer assay (consisting of 100mM HEPES (pH 8.0), 150mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) Triton X-100, 20nM PfDHODH, 18 µM decylubiquinone, 120µM DCIP), then 8ul of 5mM L-DHO was added each well in a dark room and the plate could be read using spectrophotometry with a wavelength of 600 nm every 1 minute, in 20 minutes, all procedure was performed at 25°C.

Analysis of dihydroeponemycin compound using HPLC

The analysis was carried out on a sample of fractions that had activity on the LDH assay. HPLC uses Shimadzu Prominence HPLC system (binary LC-20AB pump, UV SPD-20A detector), YMC-Pack ODS-A (YMC) chromatography column 250x4.6mm ID, S-10µm, 12 nm, eluent acetonitrile (MeCN) and standard compounds *Dihydroeponemycin* obtained from SIGMA-ALDRICH USA.

Cytotoxicity analysis using WST-8 assay

Cell suspension of DLD-1cell line culture was prepared using DMEM media with the concentrations 1.25 x 10⁵ cells / mL (2.5x 10⁴ cells / 200 µL). Then 100 µL of cell

suspension was inserted into each well of 96-well plates. The plate was placed in a 37°C incubator for 24 hours (overnight). A volume 0.4 µL of each fraction (dissolved in 100% DMSO) was added with various concentrations 80; 40; 20; 10; 5; 2.5; 1.25; 0.625; 0.3125; and 0.15625 ppm with three replicates for each concentration. The plate then placed in the incubator (37°C, 5% CO₂) for 48 hours. After 48 hours, the media was removed from the plate with the aspirator. Cells were washed with 100µL PBS for each well with suction method then a mixture of 1 mL CCK-8 and 10 mL DMEM media was made in a sterile flask. 100 µL DMEM containing CCK-8 then was added to each well. Next, the plate was placed in a 37°C incubator for 3 hours. The absorbance of each well was measured at a wavelength of 450nm by SpectraMax Paradigm.


Statistical Analysis

The statistical analysis two-way repeated-measures analysis of variances (ANOVA) and Tukey's multiple comparisons test was used to perform the difference among treatment and control groups to determine the difference in inhibition of *P. falciparum* 3D7 culture cells, PfMQO and PfDHODH enzyme using Graphpad Prism 8 software.

RESULTS AND DISCUSSION

Fractionation of *S. hygroscopicus* ethyl acetate extract

The weight of the fraction obtained from the fractionation was different for each tube with a total fraction was 47 tubes. Only 30 fractions have sufficient weight to be tested in this study. The weighed stock fraction was dissolved in methanol with the same concentration in each fraction, by making a concentration of 20,000ppm in each fraction. In this study, fractionation was carried out using column chromatography with hexane and ethyl acetate solvents. The purification step was carried out with ethyl acetate solvent and using the column chromatography to obtain pure fractions of compounds contained in crude extracts from the bacterium *Streptomyces coelicoflavus* [11,12]. Combination of solvent using hexane: ethyl acetate aimed to obtain and produce bioactive compounds from extracts of these bacteria, as well as the use of solvent gradients to obtain fractions of bacterial extracts *Actinomycetes* [13]. Purification of bacterial *Streptomyces* has been carried out using fractionation of column chromatography in the normal phase using silica gel and gradients of solvents with a 0.0: 100% system [14]. In this study fractionation was ended using methanol as flushing solvent shows in figure 1.






Figure 1. Graph of fractionation results using the FCC BUCHI Reveleris® PREP Purification System (A) The total number of fractions collected was 29 fractions using n-hexane and ethyl acetate solvents; (B) The total number of fractions collected was 18 fractions using a Methanol (MeOH) solvent, the color of each fractionation tube based on the detector used in detecting the peak (Green-ELSD; Blue-UV1; Pink-UV2; orange-UV3).

Anti-malaria activity test of *S. hygroscopicus* metabolite fraction in culture of *Plasmodium falciparum* 3D7 using enzyme lactate dehydrogenase (LDH) assay

The result of inhibition activity on *Plasmodium falciparum* culture of 30 fractions showed only 6 fractions were able to suppress the growth of *P. falciparum* culture and two of them were able to inhibit more than 50% as shows in figure 2 below from Graphpad Prism 8 analysis.




Figure 2. Six fractions of *S. hygroscopicus* metabolite that have inhibitory activity against *P. falciparum* culture using lactate dehydrogenase (P/LDH) enzyme assay

Based on figure 2, fraction fr15 and fr16 showed inhibition more than 50% with a significant different ($p=0,0019$). In Tukey's multiple comparisons test, in fraction (fr) 15, a dose of 50ppm vs 5ppm and 50ppm vs 0.05ppm showed a significant difference ($p=0,0001$; $p=0,0001$) whereas a dose of 5ppm vs 0.05ppm showed no significant difference ($p=0,9999$). Further statistical analysis of fr16 showed that a dose of 50ppm vs 5ppm had no significant difference ($p = 0,1827$) whereas at 50ppm vs 0.05ppm and 5ppm vs 0.05ppm showed significant results ($p = 0,0001$; $p=0,0001$). The LDH assay test is useful to measure the viability of a parasite against its susceptibility to drugs because the activity of pLDH (*Plasmodium* LDH) is closely related to the number of parasites [10]. LDH enzyme assay detects pLDH antigen as a specific marker of the presence of *Plasmodium*, in principle this test will specifically detect *Plasmodium* pLDH that uses 3-acetylpyridine nicotinamide as an NAD analogue and nicotinamide

adenine dinucleotide analogue. In the other hand, LDH erythrocyte human cannot use 3-acetylpyridine nicotinamide as an NAD analog and nicotinamide adenine dinucleotide analog [15]. In this study, *P. falciparum* 3D7 culture that exposed with fractions 15 and 16 decreased LDH levels by more than 50%, as in the positive control that given Atovaquon which is an antimalarial drug with similar mechanism through *Plasmodium* mitochondria.

Activity test of *S. hygroscopicus* metabolite fraction against PfdHODH and PfmQO

The activity tested for the recombinant enzymes PfdHODH and PfmQO of *P. falciparum* was carried out only in fraction samples fr15 and fr16 because both of those fractions have the highest results in inhibitory effects against *P. falciparum* 3D7 growth based on the LDH assay. In PfdHODH test, it was found that the two fractions did not show a difference in inhibition of the activity of

dihydroorotate dehydrogenase compare to the control group. Whereas in *PfMQO* test, both fractions showed significant inhibitory activity on L-malate: quinone

oxidoreductase (*PfMQO*) enzyme compared to the negative control group which can be seen in Figure 3.




Figure 3. Inhibitory activity of the *P. falciparum* L-malate enzyme: quinone oxidoreductase (*PfMQO*) enzyme assay. In fraction 15 and 16 shows significant difference among doses of 200ppm, 20ppm, and 0.2ppm ($p < 0.05$)

All doses of fraction 15 and 16 significantly differed with the control group ($p < 0.05$). In the multiple comparison results showed a significant difference of inhibition of *PfMQO* enzymes in fraction 15 between doses of 200ppm and 20ppm ($p = 0.0007$), 200ppm and 0,2ppm ($p = 0.0001$), as well as between 20 ppm and 0,2 ppm ($p = 0.0001$). Similar inhibition result showed in fraction 16, between doses of 200ppm and 20ppm ($p = 0.0001$), 200ppm and 0,2ppm ($p = 0.0001$), and between doses of 20 ppm and 0,2 ppm ($p = 0.0002$) (Figure 3). In this study, fractions that had an inhibitory effect on parasitic viability of more than 50% on the previous evaluation using the *pLDH* assay were used on *PfDHODH* and *PfMQO* assays. The results of the *PfDHODH* inhibition test did not give any inhibitory effect. This is based on the results of absorbance measurements in the *PfDHODH* test which showed no inhibition of the enzyme reaction of the fraction. As it was

known DHODH is one of the potential targets in the development of anti-malaria drugs that are quite potential [16]. At present the development of antimalarial drugs that work on the DHODH enzyme has entered into phase 2 clinical trials using the DSM265 compound obtained from the results of high-throughput screening (HTS) which showed the specific inhibitory effect on the mitochondrial DHODH enzyme [17].

High-performance liquid chromatography (HPLC) analysis of active fraction of *S. hygroscopicus* secondary metabolite

The samples analyzed by HPLC were fr15 and fr16, and a standard *dihydroeponemycin* compound. HPLC aimed to determine whether the anti-malaria activity of the fraction is due to the content of *dihydroeponemycin* or other compounds that have the potential as antimalarials.




Figure 4A. The peak of dihydroeponemycin standard





Figure 4B. The peak characteristic of fraction 15



The analysis results of standard *dihydroeponemycin* compound using MeCN (acetonitrile) as eluent with a gradient of 5% -10% - 100% for 35 minutes and an injected sample volume of 1 μ L showed a peak at *retention time*(rt) of 21,089 minutes (an area of 20,339 and a peak height of 1,387) on a detector with a wavelength of 254nm. Furthermore, it was analyzed at a detector with a wavelength of 210nm and the result showed a peak at rt of 21,088 minutes (an area of 2,859,790 and a peak height of 250,625) (Figure 4A). In the results of HPLC analysis on fraction 15 using a detector with a wavelength of 254nm, there were 6 peaks detected and at a wavelength of 210nm, there were 25 peaks detected by the detectors (Figure 4B). In the results of HPLC analysis on fraction 16 using a detector with a wavelength of 254nm, there were 3 peaks detected with the highest concentration at 3.601 minutes peak with a total concentration of 88.601%, which appeared because the peak is a DMSO solution. The other two peaks were detected on detectors with rt of 20,487 minutes and 30,751 minutes. In the results of HPLC analysis on fraction 16 using a detector with a wavelength of 210nm, there were 4 peaks detected as well as on the detector 254nm at the first peak with rt of 3,601 which was a DMSO (solvent before drying the sample), so that only the other 3 peaks will be analyzed (Figure 4C). In HPLC, acetonitrile eluent was used in analyzing the extract fraction of *S.hygroscopicus* in detecting peaks of secondary metabolite compounds in the analyzed fraction [17]. In addition, acetonitrile is an eluent used in HPLC analytic [6], showing an initial peak at fraction 16 which is a DMSO solvent at RT 4-10 minutes. When DMSO was running by HPLC using an acetonitrile eluent with a gradient concentration, DMSO was detected at vulnerable RT 0-10 minute [18]. HPLC usually using for tested the purity of

active fraction with mobile phase consisting of water – acetonitrile gradient at the flow rate 1ml/min [14]. HPLC analysis is a methods for detecting the concentration of important active compound [19]. In this present study, we recorded chromatogram of *Streptomyces* compare with standard area as showed in the following result.

Cytotoxicity Analysis using WST-8 Assay

The viability of colorectal cancer *DLD-1* cell line after being treated with ethyl acetate extract fraction of *Streptomyces hygroscopicus* subsp. *Hygroscopicus* for 48 hours at the highest dose (80 ppm) was 45.6485%, while at 9 other dose variations, the percentage of cell line viability of colorectal cancer *DLD-1* was still more than 92.9738%. These results indicated that the fraction of *Streptomyces hygroscopicus* subsp. *Hygroscopicus* needs a very high dose to be able to inhibit the proliferation process by almost 50%. The study showed that the cytotoxicity effect of fraction 15 against colorectal cancer *DLD-1* cell line occurred only at a dose of 80 ppm. This cytotoxic effect arised because of the presence of secondary metabolites contained in the ethyl acetate fraction of *Streptomyces hygroscopicus* subsp. *Hygroscopicus*. One of them is eponemycin that acts as a proteasome inhibitor with α,β -epoxyketone as an active group [20]. The inhibition of protein degradation through 20S proteasome activity by eponemycin causes inhibition of cell proliferation due to the decreased initiation of protein translation [21]. The failure of protein degradation results in cell stress response characterized by increased *Reactive Oxygen Species* (ROS) which causes inhibition of proliferation [22]. Overall the dose lower than 80 ppm is safe for the treatment of fractions of *S. hygroscopicus* metabolite (Figure 5).




Figure 5. WST-8 test after exposing for 48 hours

Showed only at a dose of 80 ppm of fraction 15 of *Streptomyces hygroscopicus* Subsp. *Hygroscopicus* gave inhibitory affect more than 50% against the DLD-1 cell line.

CONCLUSIONS

Based on the above results, fraction 15 and 16 of ethyl acetate extract of *S. hygroscopicus* was able to inhibit more than 50% growth of *P. falciparum* 3D7 *in vitro* by analyzing lactate dehydrogenase (LDH) and *Plasmodium* L-malate:quinone oxidoreductase (PfmQO) enzymes in mitochondrial membrane. It was also proven that the two fractions were non-toxic to human cells in the cytotoxicity test.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this paper.

FUNDING STATEMENT

This work was supported by the Ministry of Research, Technology and Higher Education of the Republic of Indonesia.

ACKNOWLEDGEMENTS

The authors would like to thank Parasitology, Biomedical, Pharmacology laboratory technicians and all members of the Malaria Research Group in the Faculty of Medicine, Universitas Brawijaya.

REFERENCES

- 1 Hikosaka K, Komatsuya K, Suzuki S, et al. Mitochondria of Malaria Parasites as a Drug Target. *An Overv Trop Dis*. Epub ahead of print 2015. DOI: 10.5772/61283.
- 2 Ke H, Ganesan SM, Dass S, et al. Mitochondrial type II NADH dehydrogenase of *Plasmodium falciparum* is dispensable and not the functional target of putative NDH2 quinolone inhibitors. *bioRxiv* 2018; 436881.
- 3 Hoelz LV, Calil FA, Nonato MC, et al. *Plasmodium falciparum* dihydroorotate dehydrogenase: A drug target against malaria. *Future Med Chem* 2018; 10: 1853–1874.
- 4 Hartuti ED, Inaoka DK, Komatsuya K, et al. Biochemical studies of membrane bound *Plasmodium falciparum* mitochondrial L-malate:quinone oxidoreductase, a potential drug target. *Biochim Biophys Acta - Bioenerg* 2018; 1859: 191–200.
- 5 Rivo YB, Alkarimah A, Ramadhani NN, et al. Metabolite extract of *Streptomyces hygroscopicus* *Hygroscopicus* inhibit the growth of *Plasmodium berghei* through inhibition of ubiquitin - Proteasome system. *Trop Biomed* 2013; 30: 291–300.
- 6 El-makarem HSA, Amer AA, Naby HAA. Prevalence of Some Dangerous Heavy Metal Residues and Aflatoxins in Milk and Some Dairy Products. 2019; 62: 158–165.
- 7 Khan ZJ, Khan NA, Naseem I, et al. Determination of Heavy Metals, Aflatoxins, Microbial Loads and Pesticides Residue in Sehjana (*Moringa Oleifera* Lam) Fruits/Pods. *Int Res J Pharm* 2017; 8: 203–207.
- 8 Azimi S, Basei Salehi M, Bahador N. Isolation and Identification of *Streptomyces ramulosus* from Soil and Determination of Antimicrobial Property of its Pigment. *Mod Med Lab J* 2017; 1: 36–41.
- 9 Sharma H, Parihar L. Antifungal activity of extracts obtained from actinomycetes. *J Yeast Fungal Res* 2010; 1: 197–200.
- 10 Markwalter CF, Davis KM, Wright DW. Immunomagnetic capture and colorimetric detection of malarial biomarker *Plasmodium falciparum* lactate dehydrogenase. *Anal Biochem* 2016; 493: 30–34.
- 11 Al-Dhabi NA, Esmail GA, Duraipandiyam V, et al. Isolation, identification and screening of antimicrobial thermophilic *Streptomyces* sp. Al-Dhabi-1 isolated from Tharban hot spring, Saudi Arabia. *Extremophiles* 2016; 20: 79–90.
- 12 Raghava Rao KV, Mani P, Satyanarayana B, et al. Purification and structural elucidation of three bioactive compounds isolated from *Streptomyces coelicoflavus* BC 01 and their biological activity. *Biotech* 2017; 7: 1–12.
- 13 Janardhan A, Kumar AP, Viswanath B, et al. Production of Bioactive Compounds by Actinomycetes and Their Antioxidant Properties. *Biotechnol Res Int* 2014; 2014: 1–8.
- 14 Singh V, Haque S, Khare S, et al. Isolation and purification of antibacterial compound from

- streptomyces levis collected from soil sample of north India. *PLoS One* 2018; 13: 1–10.
- 15 Ahmad SJ, Abdul Rahim MBH, Baharum SN, et al. Discovery of Antimalarial Drugs from Streptomyces Metabolites Using a Metabolomic Approach. *J Trop Med* 2017; 2017: 1–7.
 - 16 Deng X, Matthews D, Rathod PK, et al. The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N - phenylbenzamide inhibitor reveals novel binding-site interactions . *Acta Crystallogr Sect F Struct Biol Commun* 2015; 71: 553–559.
 - 17 Azerang P, Sardari S, Kobarfard F, et al. Isolation of membrane-active fraction of Streptomyces spp. From soil. *Trop J Pharm Res* 2018; 17: 849–855.
 - 18 Walker JT, Paolini DL, Segretario J. Quantitation of Residual Dimethylsulfoxide in a Drug Substance (Bisnaf ide) by Reversed-Phase High-Performance Liquid Chromatography. *J Chromatogr Sci* 1996; 34: 513–516.
 - 19 Risan MH. IDENTIFICATION ACTIVE COMPOUNDS OF BACTERIA STREPTOMYCES USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY World Journal of Pharmaceutical HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.
 - 20 Aminake MN, Arndt HD, Pradel G. The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention? *Int J Parasitol Drugs Drug Resist* 2012; 2: 1–10.
 - 21 Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. *J Cancer Prev* 2018; 23: 153–161.
 - 22 Kumari S, Badana AK, Murali Mohan G, et al. Reactive Oxygen Species: A Key Constituent in Cancer Survival. *Biomark Insights*; 13. Epub ahead of print 2018. DOI: 10.1177/1177271918755391.



Source details

Systematic Reviews in Pharmacy

Scopus coverage years: from 2010 to 2021

(coverage discontinued in Scopus)

Publisher: EManuscript Technologies

ISSN: 0975-8453 E-ISSN: 0976-2779

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Source type: Journal

CiteScore 2019

3.9



SJR 2019

0.424



SNIP 2021

0.562



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2019 counts the citations received in 2016-2019 to articles, reviews, conference papers, book chapters and data papers published in 2016-2019, and divides this by the number of publications published in 2016-2019. [Learn more >](#)

CiteScore 2019 ▼

$$3.9 = \frac{463 \text{ Citations 2016 - 2019}}{119 \text{ Documents 2016 - 2019}}$$

Calculated on 06 May, 2020

CiteScore rank 2019 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#53/169	68th
Pharmaceutical Science		


[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

Systematic Reviews in Pharmacy


Discontinued in Scopus as of 2020

COUNTRY

India



Universities and research institutions in India



Media Ranking in India

SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and Pharmaceutics
└ Pharmaceutical Science

PUBLISHER

EManuscript Technologies

H-INDEX

28

PUBLICATION TYPE

Journals

ISSN

09758453, 09762779

COVERAGE

2010-2021


INFORMATION

[Homepage](#)

[How to publish in this journal](#)

editor@sysrevpharm.org

Quartiles



SJR

2011	0.205
2012	0.253
2013	0.399
2014	0.173
2015	0.135
2016	0.132
2017	0.141
2018	0.296
2019	0.424

Total Documents

